JP7071329B2 - Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 - Google Patents

Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 Download PDF

Info

Publication number
JP7071329B2
JP7071329B2 JP2019502257A JP2019502257A JP7071329B2 JP 7071329 B2 JP7071329 B2 JP 7071329B2 JP 2019502257 A JP2019502257 A JP 2019502257A JP 2019502257 A JP2019502257 A JP 2019502257A JP 7071329 B2 JP7071329 B2 JP 7071329B2
Authority
JP
Japan
Prior art keywords
seq
sequence
polypeptide
antibody
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019502257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531701A (ja
Inventor
ヤーナ・アルブレヒト
クリスティアン・バイル
ヨーヘン・ベニンガ
カチャ・クロール
クリスティアン・ランゲ
ヴルフ・ディルク・ロイシュナー
エルコーレ・ラオ
マーリオン・シュナイダー
ペーター・ヴォネロー
ステファーヌ・ギュリフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2019531701A publication Critical patent/JP2019531701A/ja
Priority to JP2022075664A priority Critical patent/JP2022105138A/ja
Application granted granted Critical
Publication of JP7071329B2 publication Critical patent/JP7071329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019502257A 2016-07-18 2017-07-17 Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質 Active JP7071329B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022075664A JP2022105138A (ja) 2016-07-18 2022-05-02 Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305923.1 2016-07-18
EP16305923 2016-07-18
PCT/EP2017/068020 WO2018015340A1 (en) 2016-07-18 2017-07-17 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075664A Division JP2022105138A (ja) 2016-07-18 2022-05-02 Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Publications (2)

Publication Number Publication Date
JP2019531701A JP2019531701A (ja) 2019-11-07
JP7071329B2 true JP7071329B2 (ja) 2022-05-18

Family

ID=56507555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019502257A Active JP7071329B2 (ja) 2016-07-18 2017-07-17 Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質
JP2022075664A Pending JP2022105138A (ja) 2016-07-18 2022-05-02 Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022075664A Pending JP2022105138A (ja) 2016-07-18 2022-05-02 Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Country Status (24)

Country Link
US (1) US20190241657A1 (enExample)
EP (1) EP3484924A1 (enExample)
JP (2) JP7071329B2 (enExample)
KR (1) KR20190028771A (enExample)
CN (1) CN109715665A (enExample)
AR (1) AR109264A1 (enExample)
AU (1) AU2017299125A1 (enExample)
BR (1) BR112019000770A2 (enExample)
CA (1) CA3030943A1 (enExample)
CL (1) CL2019000119A1 (enExample)
CO (1) CO2019001367A2 (enExample)
CR (1) CR20190072A (enExample)
DO (1) DOP2019000011A (enExample)
EA (1) EA201990321A1 (enExample)
EC (1) ECSP19011185A (enExample)
IL (1) IL264248A (enExample)
MA (1) MA45680A (enExample)
MX (1) MX2019000844A (enExample)
PE (1) PE20190514A1 (enExample)
PH (1) PH12019500122A1 (enExample)
SG (1) SG11201900400QA (enExample)
TN (1) TN2019000015A1 (enExample)
TW (1) TWI790206B (enExample)
WO (1) WO2018015340A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022105138A (ja) * 2016-07-18 2022-07-12 サノフイ Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3247725T (lt) 2015-01-23 2020-10-12 Sanofi Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
HUE060504T2 (hu) 2016-02-03 2023-03-28 Amgen Res Munich Gmbh PSMA és CD3 bispecifikus T-sejthez kötõ ellenanyag-konstrukciók
AU2019371243A1 (en) * 2018-10-30 2021-05-27 Bruker Spatial Biology, Inc. Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies
US12264197B2 (en) 2019-03-11 2025-04-01 Janssen Biotech, Inc. Anti-Vβ17/anti-CD123 bispecific antibodies
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN111349163B (zh) * 2020-02-05 2024-07-16 北京智仁美博生物科技有限公司 针对cd123的单克隆抗体
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
BR112023002488A2 (pt) 2020-08-10 2023-05-02 Janssen Biotech Inc Materiais e métodos para produzir linfócitos biomodificados contra vírus específicos
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
WO2022144836A1 (en) * 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
EP4294829A4 (en) * 2021-02-17 2025-03-19 IGM Biosciences Inc. ANTI-CD123 BINDING MOLECULES AND THEIR USES
CN113368232B (zh) * 2021-06-02 2022-08-26 上海交通大学 多特异性抗原结合蛋白及其应用
JP2024530465A (ja) * 2021-08-06 2024-08-21 ウニバズィテート バーゼル 細胞療法に使用するための識別可能な細胞表面タンパク質変異体
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014511684A (ja) 2011-03-28 2014-05-19 サノフイ 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質
JP2014529402A (ja) 2011-08-23 2014-11-13 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
EP0497883B1 (en) 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
IL100460A (en) 1990-12-20 1997-06-10 Ixsys Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0811691B1 (en) 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
CA3036031C (en) 2000-03-06 2021-04-13 Craig T. Jordan A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
WO2009032661A1 (en) 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009299791B2 (en) * 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
ES2924722T3 (es) * 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
WO2015086548A1 (en) * 2013-12-10 2015-06-18 F. Hoffmann-La Roche Ag Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
KR102689285B1 (ko) * 2014-11-26 2024-07-31 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
LT3247725T (lt) * 2015-01-23 2020-10-12 Sanofi Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014511684A (ja) 2011-03-28 2014-05-19 サノフイ 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質
JP2014529402A (ja) 2011-08-23 2014-11-13 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MABS，2016年，Vol.8, No.5，p867-878，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968095/参照

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022105138A (ja) * 2016-07-18 2022-07-12 サノフイ Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質

Also Published As

Publication number Publication date
PE20190514A1 (es) 2019-04-10
CL2019000119A1 (es) 2019-06-14
BR112019000770A2 (pt) 2019-07-02
DOP2019000011A (es) 2019-05-15
AU2017299125A1 (en) 2019-03-07
TN2019000015A1 (en) 2020-07-15
JP2022105138A (ja) 2022-07-12
IL264248A (en) 2019-02-28
EP3484924A1 (en) 2019-05-22
SG11201900400QA (en) 2019-02-27
TWI790206B (zh) 2023-01-21
KR20190028771A (ko) 2019-03-19
CA3030943A1 (en) 2018-01-25
CN109715665A (zh) 2019-05-03
CO2019001367A2 (es) 2019-02-19
EA201990321A1 (ru) 2019-06-28
CR20190072A (es) 2019-06-25
PH12019500122A1 (en) 2019-04-15
TW201811830A (zh) 2018-04-01
MA45680A (fr) 2019-05-22
AR109264A1 (es) 2018-11-14
ECSP19011185A (es) 2019-02-28
US20190241657A1 (en) 2019-08-08
MX2019000844A (es) 2019-07-04
JP2019531701A (ja) 2019-11-07
WO2018015340A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
JP7071329B2 (ja) Ｃｄ３およびｃｄ１２３に特異的に結合する二重特異性抗体様結合タンパク質
JP7692448B2 (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
TWI793062B (zh) Ｄｌｌ３及ｃｄ３抗體構築體
HK40069391A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EA041572B1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220506

R150 Certificate of patent or registration of utility model

Ref document number: 7071329

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150